No­var­tis looks to of­fload even more of its eye prod­ucts — re­port

Fol­low­ing its re­cent trend of of­fload­ing as­sets, No­var­tis is con­tact­ing po­ten­tial buy­ers for some oph­thal­mol­o­gy as­sets, Bloomberg re­port­ed Tues­day, cit­ing peo­ple with knowl­edge of the mat­ter.

No­var­tis is work­ing with an ad­vi­sor to of­fload front-of-eye treat­ments like its dry eye drug Xi­idra, which was ap­proved in 2016 in the US but failed to get ap­proval in Eu­rope. Noth­ing is set in stone — No­var­tis could still de­cide to keep the as­sets, Bloomberg re­port­ed, and not all are in­clud­ed in a po­ten­tial sale. For ex­am­ple, Lu­cen­tis, a treat­ment for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, isn’t up for grabs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER